219 related articles for article (PubMed ID: 8788488)
1. Human psychopharmacology of N,N-dimethyltryptamine.
Strassman RJ
Behav Brain Res; 1996; 73(1-2):121-4. PubMed ID: 8788488
[TBL] [Abstract][Full Text] [Related]
2. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans.
Strassman RJ; Qualls CR; Berg LM
Biol Psychiatry; 1996 May; 39(9):784-95. PubMed ID: 8731519
[TBL] [Abstract][Full Text] [Related]
3. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.
Strassman RJ; Qualls CR; Uhlenhuth EH; Kellner R
Arch Gen Psychiatry; 1994 Feb; 51(2):98-108. PubMed ID: 8297217
[TBL] [Abstract][Full Text] [Related]
4. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects.
Strassman RJ; Qualls CR
Arch Gen Psychiatry; 1994 Feb; 51(2):85-97. PubMed ID: 8297216
[TBL] [Abstract][Full Text] [Related]
5. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
[TBL] [Abstract][Full Text] [Related]
6. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
7. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
Carbonaro TM; Eshleman AJ; Forster MJ; Cheng K; Rice KC; Gatch MB
Psychopharmacology (Berl); 2015 Jan; 232(1):275-84. PubMed ID: 24985890
[TBL] [Abstract][Full Text] [Related]
8. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
[TBL] [Abstract][Full Text] [Related]
9. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
Frecska E; Szabo A; Winkelman MJ; Luna LE; McKenna DJ
J Neural Transm (Vienna); 2013 Sep; 120(9):1295-303. PubMed ID: 23619992
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of ayahuasca administered in two repeated doses.
Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
[TBL] [Abstract][Full Text] [Related]
11. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
Heekeren K; Neukirch A; Daumann J; Stoll M; Obradovic M; Kovar KA; Geyer MA; Gouzoulis-Mayfrank E
J Psychopharmacol; 2007 May; 21(3):312-20. PubMed ID: 17591658
[TBL] [Abstract][Full Text] [Related]
12. Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).
Witowski CG; Hess MR; Jones NT; Pellitteri Hahn MC; Razidlo J; Bhavsar R; Beer C; Gonzalez-Velazquez N; Scarlett CO; Wenthur CJ; von Salm JL
Eur J Pharm Sci; 2024 Aug; 199():106803. PubMed ID: 38788435
[TBL] [Abstract][Full Text] [Related]
13. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.
Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Montero M; Callaway JC; Barbanoj MJ
Psychopharmacology (Berl); 2001 Feb; 154(1):85-95. PubMed ID: 11292011
[TBL] [Abstract][Full Text] [Related]
14. Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users.
Cakic V; Potkonyak J; Marshall A
Drug Alcohol Depend; 2010 Sep; 111(1-2):30-7. PubMed ID: 20570058
[TBL] [Abstract][Full Text] [Related]
15. Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.
Bouso JC; Pedrero-Pérez EJ; Gandy S; Alcázar-Córcoles MÁ
Hum Psychopharmacol; 2016 Sep; 31(5):356-72. PubMed ID: 27470427
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study.
Riba J; McIlhenny EH; Bouso JC; Barker SA
Drug Test Anal; 2015 May; 7(5):401-6. PubMed ID: 25069786
[TBL] [Abstract][Full Text] [Related]
17. Opioid-hallucinogen interactions.
Domino EF
Pharmacol Biochem Behav; 1986 Feb; 24(2):401-5. PubMed ID: 3006089
[TBL] [Abstract][Full Text] [Related]
18. Hallucinogens as discriminative stimuli: a comparison of 4-OMe DMT and 5-OMe DMT with their methythio counterparts.
Glennon RA; Young R; Benington F; Morin RD
Life Sci; 1982 Feb; 30(5):465-7. PubMed ID: 6801410
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine - Implications for dose considerations.
Eckernäs E; Timmermann C; Carhart-Harris R; Röshammar D; Ashton M
Clin Transl Sci; 2022 Dec; 15(12):2928-2937. PubMed ID: 36088656
[TBL] [Abstract][Full Text] [Related]
20. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
